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To assess the potential of an in vivo, adenovirus-
mediated gene therapy approach for the treatment of 
malignant melanoma, the efficacy of adenovirus-
mediated herpes simplex virus thymidine kinase gene 
(HSV -Ek) transfer and administration of ganciclovir 
(GCV) was investigated using a nude mouse model. 
Initially, B16 murine melanoma cells were efficiently 
transduced in vitro by a recombinant replication-
defective adenovirus containing the HSV -tk gene 
(ADVIRSVtk), and rendered sensitive to cell killing 
by 10 ILg/ml GCV. A significant "bystander effect" 
was observed at low multiplicity of infection in com-
parison of cell killing to control B16 transduction 
by adenovirus containing the l1-galactosidase gene 
he incidence of malignant melanoma in Caucasians is 
increasing yearly by 2-3%, second only to lung 
cancer, and predictions suggest that in the United 
States up to 1 in 90 individuals will develop skin 
melanoma by the year 2000 [1,2]. In addition, unlike 
most other cancers, melanoma frequently affects younger individ-
uals [3]. Currently, treatment of malignant melanoma is problem-
atic due to a high propensity for metastatic spread and resistance of 
this tumor type to most chemotherapeutic regimes [3,4]. Despite 
many years of study, therapeutic success rates to date center on 
surgical treatment of early, stage I melanoma [2], with little 
effective therapy available for stage III melanoma [3]. Given the 
prediction that ozone depletion is likely to increase the incidence of 
all skin malignancies including melanoma [5,6], the development of 
effective molecular therapies to treat this potential epidemic are 
highly desirable. 
One potentially useful strategy is the application of somatic cell 
gene therapy techniques that transduce tumor cells with a variety of 
immunologic or drug sensitizing "suicide" genes [7,8]. One exam-
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(ADVIRSV-I1-gal). In vivo, melanoma~ established 
from subcutaneous injection of 4 X 105 B16 cells were 
injected after 14 d with 1 X 1010 ADVIRSV-tk viral 
particles. Subsequent treatment for 6 d with GCV 
resulted in an inhibition of melanoma growth, with 
an approximately 40-50% reduction in melanoma 
volume in comparison to controls in repeated exper-
iments. These data demonstrate that adenovirus-
mediated gene transfer can function as an efficient 
delivery system to reduce established tumor burden 
in vivo. This result may hold significant promise for 
the development of effective in situ gene therapy for 
melanoma in humans. Key words: gene therapy/ganciclo-
vir/adenovirus. ] Invest Dermatol 104:313-317, 1995 
pIe of the latter is transfer of the herpes simplex virus thymidine 
kinase (HSV -tk) gene followed by administration of ganciclovir 
(GCV) [9,10]. This normally non-toxic drug, an analogue of 
guanosine, is phosphorylated by HSV - tk and converted to an 
intermediate that inhibits DNA synthesis by acting as a chain 
terminator [9], killing dividing cells [10]. Thus, this approach is 
eminently suitable for the treatment of rapidly growing solid 
tumors that are invading normal tissues comprised largely of 
quiescent cells [10]. Furthermore, by employing this particular 
combination, not all tumor cells need to be transduced due to the 
existence of the "bystander effect" [11], where tumor cells in close 
proximity to HSV -tk transduced cells are also killed on release of 
phosphorylated GCV [11]. Recently, melanoma cells have demon-
strated a susceptibility to this approach. By transfection of the 
HSV-tk gene, regulated by a tyrosinase promoter into B16 murine 
melanoma cells, transfectants become sensitized to GCV treatment 
both in vitro and in vivo [12]. 
To be useful in a clinical setting, direct delivery to tumor cells in 
vivo is necessary and, most recently, this has been achieved by the 
use of replication defective retroviral vectors [13,14]. Although 
retroviral vectors mediate stable, integrated gene transfer exclu-
sively into dividing cells [15], this delivery system has several 
limiting characteristics, including low viral titers and the possibility 
of insertional mutagenesis [15]. In contrast, adenoviral vectors 
(AD V) can be produced at very high titers and have no significant 
potential for integration or insertional mutagenesis [16] . Recently, 
experimental gliomas were successfully treated in vivo using adeno-
viral-mediated transduction of tumor cells with HSV -tk and treat-
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ment with GCV [17]. Remarkably. virtual total glioma regression 
was observed [17]. 
We now report the successful application of this in vivo adeno-
viral-mediated gene delivery approach to the treatment of estab-
lished melanomas in nude mice. Following preliminary in vitro 
experiments. using the ADV IRSV -13-gal virus to confirm efficient 
adenoviral transduction of B 16 cells. B 16 melanomas were trans-
duced in vivo by ADV IRSV -tk and their growth was significantly 
inhibited by GCV treatment in comparison to melanomas growing 
in control or untreated animals. A significant bystander effect was 
observed in vitro and is suggested in vivo by comparing the 40-50% 
reduction in growth rate to the number of cells transduced by 
control ADV IRSV -13-gal. The availability of sufficiently high titers 
of adenovirus. allowing gene delivery by simple tumor injection. 
suggests that an adenovirus-mediated gene therapy approach may 
become an effective in vivo treatment for malignant melanoma. 
MATERIALS AND METHODS 
Cell Culture and Viral Transduction In Vitro B16 murine melanoma 
cells were routinely cultured in Eagle's minimal essential medium supple-
mented with 10% (v/v) fetal bovine serum as described previously [lS]. The 
construction and generation of recombinant, replication defective adenovi-
rus ADV /RSV -tk and ADV /RSV -f3-gal have been described previously 
[17]. Viral titer was determined by absorbance at 260 om [17]. 
To determine adenoviral infectivity, B16 cells were plated at 3 X 105 per 
35-mm dish and 24 h later, incubated with ADV /RSV -f3-gal [19] at a 
multiplicity of infection (MOl) of 30-9000 in serum-free medium for 3 h. 
Three days later, cells were fixed in 2% paraformaldehyde/0.2% glutaral-
dehyde (v/v) at 4°C for 10 min, and the number of cells transduced was 
assessed by staining cultures with 5-bromo-4-chloro-3-indoyl f3-D-galacto-
sidase (X-gal) (Fisher Biotech, Fairlawn, NJ) and ferrolferric isothiocyanate 
solution essentially as described [20]. The average number of transduced 
blue cells per dish was determined by counting 30 separate microscope 
fields. In triplicate dishes, adenoviral transduction efficiency was also 
assessed by determination of f3-gal enzymic activity in cell lysates . Briefly, 
protein was extracted by resuspending cell pellets in 100 J,LI of 0.25 M Tris, 
pH 7.S, freeze-thawed using a dry ice/ethanol bath, and centrifuged to 
remove cell debris. Protein concentration was standardized using the 
Bradford assay, and f3-gal activity was assessed by a sensitive chemilurni-
nescent f3-gal reporter assay, performed according to manufacturer's in-
structions (Galacto-Light, Tropix, Bedford, MA) [21]. 
To determine adenoviral transduction and GCV cytotoxicity in vitro, cells 
were plated at 5 X 104 per 35-mm dish and 24 h later incubated with 
ADV/RSV-tk for 3 h at an MOl range of 1-3000. The following day, cells 
were placed in medium containing 10 ILg/ml GCV (Cytovene, Syntex, Palo 
Alto, CA) and the number of surviving cells determined after 6 d by trypan 
blue exclusion. 
In Vivo Experinlents Melanomas were established in 6 - S week old 
athymic nude mice by subcutaneous injection of 4 X 105 B 16 melanoma 
cells. At 14 d, melanomas typically reached a diameter of 6-S mm as 
determined by micrometer-caliper measurement, and were injected with 
ADV /RSV -tk, ADV /RSV -f3-gal viruses or buffer alone as described [17]. 
Briefly, 1 X 1010 viral particles dissolved in 75 ILl Tris-buffered saline, 
containing 20 J,Lg/ml polybrene, were injected into the tumor center using 
a Hamilton syringe with a 30 gauge needle. To minimize leakage, injections 
were performed slowly (1 J,Ll/3 seconds) and the needle removed slowly 
after a 30-second delay. The next day, virus and buffer-injected animals 
were randomized with respect to initial tumor size and divided into 
GCV-treated (100 mg/kg injected (intraperitoneally) twice daily in isotonic 
sodium chloride) or mock, isotonic sodium chloride-treated groups. GCV 
treatment continued for 6 d when animals were sacrificed and each resultant 
melanoma was carefully measured with a micrometer-caliper along three 
axes. For histologic evaluation, tumor material was fixed in Carnoy's 
solution (chloroform/acetic acid/ethanol 3:1:6 v/v) embedded in paraffin, 
sectioned, and stained with hematoxylin and eosin. To determine f3-gal 
activity in vivo, tumor material was fixed by a I-h incubation at 4°C with 2% 
paraformaldehyde/0.2% glutaraldehyde, incubated overnight with X-gal 
[20], sectioned, and lightly counterstained with nuclear fast red. Statistical 
analysis of initial and final tumor volume was performed by the Mann-
Whitney U test with a level of significance set to 0.05. 
RESULTS AND DISCUSSION 
In Vitro Quantitation of B16 Melanoma Cell Transduction 
by Recombinant Adenovirus The ability of adenovirus to 
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transduce B 16 melanoma cells was assessed in vitro by transduction 
with ADV IRSV -13-gal virus [17,19] and subsequent incubation of 
infected cultures with X-gal [20], or by performing a chemilumi-
nescence assay to determine l3-gal activity [21]. At MOl below 300, 
where an average of 24% of cells stained blue (Fig 1A), few 
X-gal-stained cells per dish were obtained (e.g., at an MOl of 30, 
approximately 0.2%; at an MOl of 100, approximately 1.3%). but 
quantitation using a chemiluminescence assay at these low MOl 
detected l3-gal activity (Fig 1A). At an MOl of 1000. approxi-
mately 64% of B16 cells stained with X-gal. which increased to 
95% at 3000 MOl. and there was a corresponding large increase in 
l3-gal enzymic activity (Fig 1A). However. at 9000 MOl. signifi-
cant adenoviral cytotoxicity was observed as determined by B 16 
cell morphology. cell count. and trypan blue exclusion assays (not 
shown). These data demonstrated that B16 melanoma cells were 
efficiently transduced by adenovirus. although the MOl required to 
transduce large numbers ofB16 cells in vitro (>1000) appears to be 
higher than that reported previously for the transduction of glioma 
cells [17]. mesothelioma cells [22]. or keratinocytes [23]. This 
apparent resistance of B 16 cells to adenoviral transduction. requir-
ing a higher viral infectivity. was not problematic for an effective 
treatment in vivo. given the availability of high adenoviral titers and. 
in particular. the existence of a strong bystander effect (see below). 
In Vitro Cytotoxicity of GCV in HSV-tk-Transduced B16 
Melanoma Cells and Demonstration of a Bystander Effect 
To determine whether adenovirus-mediated transduction with the 
HSV -tk gene would render B 16 cells sensitive to cell killing by 
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Figure 1. In vitro transduction ofB16 melanoma cells by adenovi-
rus. A) f3-gal activity following transduction of B 16 cells by ADV /RSV-
f3-gal at the MOl indicated. f3-gal activity was determined by a chemilu-
minescence assay and expressed as enzymatic activity per J,Lg protein. Data 
is pooled from triplicate dishes in two separate experiments. Numbers on 
bars indicate the approximate percentage of X-gal stained cells per dish at 
each MOl, determined by averaging the counts from 30 separate micro-
scope fields. B) GCV cell killing ofB16 cells transduced with ADV /RSV-tk 
at the MOl indicated. B16 cells were seeded at 5 X 104 in 35-mm dishes and 
the next day incubated for 3 h with adenovirus; 24 h later, infected cells 
were treated with medium containing 10 J,Lg/ml GCV (solid bars). Six days 
later, viable cells were counted. Data is pooled from triplicate dishes in two 
separate experiments. 
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GCV, cells were transduced with ADV IRSV-tk [17] at varying 
MOl and cultured in media containing 10 /-Lg/ml GCV. After 6 d , 
the number of surviving B 16 cells were counted and trypan blue 
exclusion assays demonstrated that more than 95% of cells were 
killed at an MOl of 100-300, and a significant number (p = 0.001) 
killed with an MOl as low as 1 (Fig IB). No significant effect of 
GCV treatment alone was observed (Fig IB). In comparison to the 
control ADV IRSV -{3-gal infections performed in parallel, this cell 
killing result clearly indicated the presence of the so-called "by-
stander effect." In repeated experiments, ADV IRSV -tk transduc-
tion at MOl between 3 and 100, where less than 2% of B 16 cells 
were transduced (as determined by X-gal staining), almost all B16 
cells were rendered sensitive to cell killing by GCV (Fig IB). This 
appears to be a relatively strong exhibition of the bystander effect, 
and indicates that B 16 melanoma cells may be particularly sensitive 
to cytotoxic effects of phosphorylated GCV in vitro, perhaps as a 
consequence of their rapid proliferation rate [18]. This would 
appear to offset significantly the lower adenoviral infectivity exhib-
ited by B 16 cells in vitro ( above), and was encouraging for the 
efficacy of in vivo treatment. 
In Vivo Inhibition of Established B16 Melanoma Growth by 
ADV/RSV -tk Transduction and Treatment with GCV 
Based on the efficient infectivity and strong bystander effect 
observed in vitro, the effi cacy of this adenovirus/tk/GCV approach 
to treat experimental melanomas ill vivo was assessed. Athymic 
nude mice were injected subcutaneously with 4 X 105 B16 cells and 
allowed to grow for 14 d . As previously documented, B16 mela-
nomas grew very rapidly [18], producing a tumor diameter between 
6 - 8 mm at the time of viral infection (Fig 2A), and were much 
larger than gliomas treated previously [17]. Routinely, 15 tumor-
bearing animals comprised each experimental group, and melano-
mas were directly injected with either 1 X 1010 ADV IRSV-tk or 
control ADV IRSV -{3-gal viral particles or buffer alone. Animals 
were then placed into GCV - treated or mock (isotonic sodium 
chloride solution)-treated groups, and typical results of melanoma 
growth after 6 d of GCV treatment from two separate experiments 
are shown in Fig 2 , and quantitated in Fig 3. In these experiments, 
all animals in the mock-infected/GCV-treated or ADV IRSV-tk-
infected/mock-treated groups developed very large melanomas 
(Fig 2B) , with an average fourteenfold increase in tumor volume in 
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Figure 3. Quantitation of melanoma volume reduction following 
transduction of established melanomas with ADVIRSV-tk and 
GCV treatment. Tumors were measured with a micrometer caliper at the 
time of adenovirus or buffer injection and again following 6 d of GCV or 
NaCI treatment as indicated . Data is presented from two of three indepen-
dent experiments and significance values (Mann-Whitney U test) are a 
comparison of the tumor volume in each experimental group compared to 
the buffer/NaCl control group. For experiment 1 the average initial tumor 
volume at the time of virus injection was 152 2: 10 mm3 and in experiment 
2 was 240 2: 22 mm3 . In experiment 1, the mean tumor volume increase on 
combining all control m elanoma volumes versus treated m elanomas was 
14.1 fold versus 7.4 fold, and in experiment 2 was 6.1 fold versus 3.7 fold. 
i.t., intratumor injection; i.p., intraperitoneal injection. No significant effect 
of GCV cytotoxici ty on melanoma growth rate was observed in parallel 
experiments employing control ADV /RSV -{3-gal. 
experiment 1 and a sixfold increase in experiment 2 (Fig 3). 
Conversely, GCV-treated animals bearing melanomas transduced 
with ADV IRSV-tk virus exhibited a significant (p = 0.01) reduc-
tion in melanoma size and growth rate (Fig 2C), with only a 7.4 
(experiment 1) or 3.7 (experiment 2) fold increase in tumor volume 
(Fig 3) . Often, treated melanomas displayed a central, necrotic 
Figure 2. Macroscopic appearance of nude mouse B16 melanomas. A) A typical example of melanoma size (6-7-mm diameter) at the time of virus 
injection after 14-d growth following subcutaneous injection of 4 X 105 B16 cells. B) Large melanoma produced in the ADV /RSV-tk transduction group 
without GCV treatment. TIllS was also typically produced by ADV /RSV -(3-gal transduction with or without GCV treatment or in mock-infected groups. 
Tumor burden necessitated sacrifice of several of these control animals. C) A typical B 16 melanoma transduced with ADV / RSV -tk and treated twice daily 
with 100 mg/kg GCV for 6 d demonstrates approximately 50% reduction in growth rate compared to B. Note also the concave, ulcerated, necrotic center. 
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concave area (Fig 2Q, and, in repeated experiments, melanoma 
growth rate was typically reduced by approximately 40-50%. No 
significant effect of GCV treatment on melanoma growth was 
observed in tumors transduced in parallel with control ADV IRSV-
f3-gal virus (not shown). 
Although at first sight an increase in tumor size of three- to 
sevenfold does not appear to be satisfactory, this treatment repeat-
edly resulted in halving the tumor-growth rate, giving rise to a 
significantly smaller tumor burden (Fig 2B versus C). Moreover, 
this 40-50% reduction in growth rate may reflect the presence of an 
in vivo bystander effect, given a comparison of the number of 
melanoma cells typically transduced (1-2%), determined by X-gal 
staining of control melanomas infected with ADV IRSV -f3-gal (Fig 
4A), to the degree of necrosis observed histologically (Fig 4B). It is 
likely that the continued melanoma growth in treated animals 
reflects the aggressive nature of the population of B 16 cells that 
were not transduced by the ADV IRSV -tk virus in vivo. This idea 
is supported by a third experiment originally designed to assess 
the potential for the therapy of larger (10-12-mm diameter) 
melanomas. HSV -tk/GCV treatment resulted in the appearance 
of "dumbbell" shaped tumors with a dead, necrotic middle, 
giving rise to essentially the growth of two separate melanomas. 
In this experiment, untreated melanoma volumes were two- to 
threefold larger than the melanoma volumes obtained in treated 
animals. Thus, even for larger melanomas, an approximately 
50% decrease in growth rate was recorded. Furthermore, it 
should be noted that this aggressive B16 growth rate, rapidly 
outstripping the blood supply, impaired the ability to distinguish 
histologically between the high degree of necrosis observed in 
treated animals (Fig 4B) to that of spontaneous necrosis ob-
served in untreated controls. 
These data indicate that adenovirus-mediated gene delivery has 
the potential to become an effective, in vivo therapeutic regime for 
treatment of human melanoma. Hart and co-workers originally 
demonstrated the efficacy of a suicide gene treatment regime for 
melanoma employing an ex vivo approach [12]. B16 melanoma cells 
were transfected in vitro with the HSV -tk gene expressed from a 
melanocyte-specific tyrosinase promoter. Following subcutaneous 
injection, and treatment of mice with GCV, an inhibition of 
melanoma growth was observed, due to a significant bystander 
effect [12]. The novel use of adenoviral vectors in our study allows 
this suicide gene therapy to be directly applied to treat established 
melanomas in vivo. 
The encouraging results obtained to date in this nude mouse 
model shows that the availability of high adenoviral titer allows in 
vivo gene delivery by a simple injection technique, and demon-
strates efficacy of HSV -tk and GCV treatment on melanoma 
growth inhibition. Of course, although confirming the principle of 
adenovirus-mediated gene delivery in vivo, a suicide gene therapy 
alone would be insufficient to treat melanoma in humans because it 
cannot specifically address the metastatic nature of melanoma, the 
most significant aspect of the disease in terms of survival [2,4]. 
Thus, a combination adenovirus-mediated gene therapy, involving 
an immunogenic aspect, can be factored into this experimental 
HSV -tkl GCV -treatment regime, by co-transduction of B 16 mela-
nomas in syngeneic, immune-competent animals with adenoviruses 
containing HSV -tk and an immunologic gene to attract tumor 
inflltrating lymphocytes or antigen-specific T cells. Recently, sev-
eral cytokines have been assessed for the ability to enhance the 
immunogenicity of tumor cells in vivo (reviewed in [8]). Animal 
model studies have demonstrated that tumor cell lines transduced 
with interleukin 2 (IL-2) [24], and specifically B16 melanoma cells 
transduced with IL-4, IL-6, or granulocyte-macrophage colony-
stimulating factor (GM-CSF), secrete these cytokines and render 
the animal immune to a second challenge with the parental tumor 
cell lines [25]. 
Therefore, future experiments will assess whether HSV-tk/GCV 
treatment can be coupled to a specific adenoviral-mediated immu-
notherapy approach. This combined approach has the potential to 
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Figure 4. In vivo melanoma cell transduction by ADVIRSV-f3-gal 
and histopathology of ADVIRSV-tk transduced, GCV-treated mel-
anomas: demonstration of an in vivo bystander effect. A) ADV IRSV-
{3-gal transduced melanoma section stained with X-gal. Note {3-galactosi-
dase activity in approximately 1-2% of cells. B) Hematoxylin and eosin-
stained section of a typical ADV/RSV-tk-transduced/GCV-treated B16 
melanoma shows the junction between a large area of necrosis and 
malignant melanoma, and indicates the presence of a strong bystander 
effect. q ADV IRSV -tk-transduced control melanoma, without GCV 
treatment, shows little signs of endogenous necrosis or adenoviral cytotox-
icity in this example. However, it should be noted that certain areas of 
control melanomas possessed areas of spontaneous necrosis , typical of 
rapidly growing B16 melanomas. Bar, 60 /Lm. 
both arrest melanoma growth and enhance the host immune 
response, which may effectively combat the problem of melanoma 
recurrence from tumor microinvasion and provide a surveillance 
system to detect and eliminate metastatic lesions. 
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ANNOUNCEMENT 
The 44th Annual Symposium on the Biology of Skin, entitled "Skin Cancer: Pathomechanisms. 
Epidemiology and Clinical Manifestations, and New Approaches to Therapy," will be held July 
11-15, 1995 at Snowmass Village, Colorado. 
This meeting will provide a comprehensive review of the cellular and molecular biology of 
carcinogenesis, the biology of skin cancers, and modern approaches to treatment. 
Formal presentations by invited speakers, invited poster presentations, and free poster presentations 
will be included. 
Abstracts for the free poster session should be submitted by May 15, 1995 on SID or ESDR abstract 
forms to: 
David A. Norris, M.D. 
44th Annual Symposium on the Biology of Skin 
Box B 144 Department of Dermatology 
University of Colorado School of Medicine 
4200 East Ninth Avenue 
Denver CO 80262. 
